<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jiao X</submitter><funding>the Young Start-up Foundation of Changzheng Hospital</funding><funding>National Natural Science Foundation of China</funding><funding>Shanghai Pujiang Program</funding><funding>International and Cooperation Program of China</funding><pagination>570</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5960197</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>BACKGROUND:A-disintegrin and metalloproteinases (ADAMs) are members of a family of multidomain transmembrane and secreted proteins. Specific ADAMs are upregulated in human cancers and correlated with tumor progression and poor outcome, but rarely studied in human hilar cholangiocarcinoma (HC). This study aimed to explore the expression profiles of ADAMs and their potential underlying mechanisms promoting cancer progression. METHODS:mRNA expression of ADAM-9, - 10, - 11, - 12, - 15, - 17, - 28, and - 33 was analyzed in human hilar cholangiocarcinoma (HC) samples. Immunohistochemical (IHC) analysis was used to detect the expression of ADAM-10, - 17, - 28, and FoxM1 in HC. The regulation of ADAM-17 by FoxM1 and their functional study was investigated in vivo and in vitro. RESULTS:ADAM-10, - 1</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1.</pubmed_title><pmcid>PMC5960197</pmcid><funding_grant_id>81572856</funding_grant_id><funding_grant_id>2015CZQN07</funding_grant_id><funding_grant_id>13PJD002</funding_grant_id><funding_grant_id>2014DFA33010</funding_grant_id><pubmed_authors>Qian J</pubmed_authors><pubmed_authors>Wei P</pubmed_authors><pubmed_authors>Fang W</pubmed_authors><pubmed_authors>Yu W</pubmed_authors><pubmed_authors>Yu G</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Jiao X</pubmed_authors></additional><is_claimable>false</is_claimable><name>ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1.</name><description>BACKGROUND:A-disintegrin and metalloproteinases (ADAMs) are members of a family of multidomain transmembrane and secreted proteins. Specific ADAMs are upregulated in human cancers and correlated with tumor progression and poor outcome, but rarely studied in human hilar cholangiocarcinoma (HC). This study aimed to explore the expression profiles of ADAMs and their potential underlying mechanisms promoting cancer progression. METHODS:mRNA expression of ADAM-9, - 10, - 11, - 12, - 15, - 17, - 28, and - 33 was analyzed in human hilar cholangiocarcinoma (HC) samples. Immunohistochemical (IHC) analysis was used to detect the expression of ADAM-10, - 17, - 28, and FoxM1 in HC. The regulation of ADAM-17 by FoxM1 and their functional study was investigated in vivo and in vitro. RESULTS:ADAM-10, - 1</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 May</publication><modification>2025-04-04T13:02:54.047Z</modification><creation>2019-03-26T23:38:30Z</creation></dates><accession>S-EPMC5960197</accession><cross_references><pubmed>29776401</pubmed><doi>10.1186/s12885-018-4294-9</doi></cross_references></HashMap>